Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

PL EN


Preferences help
enabled [disable] Abstract
Number of results

Journal

2024 | 11 | 1 | 47-53

Article title

Treatment of conjunctivitis in the 21st century

Authors

Content

Title variants

Languages of publication

Abstracts

EN
One of the reasons for the development of antibiotic resistance in ophthalmology is the indiscriminate use of antibiotics in the treatment of conjunctivitis, among other things. Therefore, in infectious conjunctivitis, the first-line treatment should be antiseptics rather than antibiotics. This should significantly reduce the development of antibiotic resistance, but also increase the effectiveness of treatment.

Publisher

Journal

Year

Volume

11

Issue

1

Pages

47-53

Physical description

Dates

published
2024

Contributors

author
  • Department of Ophthalmology, Military Institute of Aviation Medicine
  • Center for Pediatric Ophthalmology

References

  • Chang Q, Wang W, Regev-Yochay G et al. Antibiotics in agriculture and the risk to human health: how worried should we be? Evolutionary Applications. 2015; 8: 240-7.
  • Antimicrobial Resistance Collaborators: Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399: 629-55. https://doi.org/10.1016/S0140-6736(21)02724-0.
  • Milder E, Vander J, Shah C et al. Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology. 2012; 119(7): 1420-4.
  • Grosso A, Bandello F, Ceruti P et al. Choosing wisely: Antibiotic use in ophthalmic surgery. Rethinking the use of antibiotics before and after surgery. Special Report. Retina Today. 2019; March: 48-53.
  • Grzybowski A, Koerner JC, George MJ. Postoperative endophthalmitis after cataract surgery: A worldwide review of etiology, incidence and the most studied prophylaxis measures. Expert Rev Ophthalmol. 2019; 14(4-5): 247-57. https://doi.org/10.1080/17469899.2019.1674140.
  • Prost M, Semczuk K. Antybiotykooporność szczepów bakteryjnych worka spojówkowego u dzieci. Klin Oczna. 2005; 107: 418-20.
  • Grzybowski A, Brona P, Kim SJ. Microbial flora and resistance in ophthalmology: a review. Graefes Arch Clin Exp Ophthalmol. 2017; 255: 851-62.
  • Prost M. Antibiotic therapy of bacterial conjunctivitis – a practical approach. Ophthatherapy. 2021; 8: 240-6.
  • Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol. 2004; 49(suppl 2): S79-83.
  • Blondeau JM. Fluoroquinolones: Mechanism of action, classification, and development of resistance. Surv Ophthalmol. 2004; 49(suppl 2): S73-8.
  • Filipek B, Prost M. Leki stosowane w leczeniu chorób infekcyjnych oczu. In: Prost M, Jachowicz R, Nowak JZ (ed). Kliniczna farmakologia okulistyczna. 2 ed. Elsevier, Wrocław 2016.
  • Rose PW, Harnden A, Brueggemann AB et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial. Lancet. 2005; 366: 37-43.
  • Honkila M, Koskela U, Kontiokari T et al. Effect of topical antibiotics on duration of acute infective conjunctivitis in children: a randomized clinical trial and a systematic review and meta-analysis. JAMA Network Open. 2022; 5(10): e2234459.
  • Chen YY, Liu AHS, Nurmatov U et al. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2023; 3: CD001211. http://doi.org/10.1002/14651858.CD001211.pub4.
  • Prost M, Szot M, Dudek D et al. Wiarygodność stosowania leków jako problem terapeutyczny w leczeniu jaskry w Polsce. Okulistyka. 2009; 1: 26-9.
  • Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: Results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007; 33: 978-88.
  • Barry P, Cordovés L, Gardner S. ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: Data, dilemmas and conclusions. Eur Soc Cataract Refract Surg Dublin 2013. Available from: http://www.escrs.org/downloads/endophthalmitis-guidelines.pdf.
  • Grzybowski A, Kupidura-Majewski K. Znaczenie kropli antybiotykowych w profilaktyce okołooperacyjnej zapalenia wnętrza gałki po operacjach zaćmy. Ophthatherapy. 2019; 6(3): 147-51. http://doi.org/10.24292/01.OT.300919.01.
  • Kanclerz P, Myers WG. Chlorhexidine and other alternatives for povidone-iodine in ophthalmic surgery: review of comparative studies. J Cataract Refract Surg. 2022; 48: 363-9. http://doi.org/10.1097/j.jcrs.0000000000000754.
  • Borgia A, Mazucca D, Della Corte M et al. Prophylaxis of Ocular Infection in the Setting of Intraocular Surgery: Implications for Clinical Practice and Risk Management. Ophthalmol Ther. 2023; 12: 721-34. http://doi.org/10.1007/s40123-023-00661-9.
  • Szumny D. Will antiseptics become the standard in ophthalmology in the future? Ophthatherapy. 2023; 10(3): 190-4.
  • Kanclerz P, Myers WG. Potential substitutes for povidone-iodine in ocular surgery. Eye. 2021; 35: 2657-9.
  • Parikh SR, Parikh RS. Chemical disinfectants in ophthalmic practice. Indian J Ophthalmol. 2021; 69: 510-6.
  • Koburger T, Hübner H-N, Braun M et al. Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. J Antimicrob Chemother. 2010; 65(8): 1712-9. http://doi.org/10.1093/jac/dkq212.
  • Ferrara M, Gatti F, Lockington D et al. Antimicrobials and antiseptics: Lowering effect on ocular surface bacterial flora – A systematic review. Acta Ophthalmologica. 2023; 00: 1-14. http://doi.org/10.1111/aos.15732.
  • Spadea J, Zanotto E, Cavallo R et al. Effectiveness of liposomal ozonized oil in reducing ocular microbial flora in patients undergoing cataract surgery. J Cataract Refract Surg. 2021; 47(12): 1548-55. http://doi.org/10.1097/j.jcrs.0000000000000672.
  • Caruso I, Eletto D, Tosco A et al. Comparative Evaluation of Antimicrobial, Antiamoebic and Antiviral Efficacy of Ophthalmic Formulations. Microorganisms. 2022; 10(6): 1156. https://doi.org/10.3390/microorganisms10061156.
  • Romano V, Ferrara M, Aragona E et al. Topical antiseptics in minimizing ocular surface bacterial load before ophthalmic surgery: a randomized controlled trial. Am J Ophthalmol. 2024; 261: 165-75. https://doi.org/10.1016/j.ajo.2024.01.007.
  • Pinna A, Gavino Donadu M, Usai D et al. In Vitro Antimicrobial Activity of a New Ophthalmic Solution Containing Hexamidine Diisethionate 0.05% (Keratosept). Cornea. 2020; 39(11): 1415-9.
  • Lachota M, Hautz W. Ocusept jako potencjalna alternatywa dla antybiotyków w leczeniu ostrego infekcyjnego zapalenia spojówek u dzieci. Standardy Medyczne/Pediatria. 2023; 20: 575-8.
  • Isenberg J, Apt L, Valenton M et al. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children. Am J Ophthalmol. 2002; 134(5): 681-8. https://doi.org/10.1016/S0002-9394(02)01701-4.
  • Pepose JS, Ahuja A, Narvekar A et al. Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis. Am J Ophthalmol. 2018; 194(10): 7-15.
  • Pepose JS, Narvekar A, Liu W et al. A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis. Clin Ophthalmol. 2019; 13: 535-44.

Document Type

Publication order reference

Identifiers

Biblioteka Nauki
56309545

YADDA identifier

bwmeta1.element.ojs-doi-10_24292_01_OT_300324_1
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.